Full-Time

Scientist I/II

Vector & Molecular Biology

Confirmed live in the last 24 hours

Tr1X

Tr1X

11-50 employees

Develops cellular immunotherapies for autoimmune diseases

Biotechnology
Healthcare

Junior, Mid

No H1B Sponsorship

San Diego, CA, USA

Category
Biology Lab & Research
Biology & Biotech
Required Skills
Data Analysis
Requirements
  • A PhD in molecular biology, biochemistry, virology, microbiology, or related field with a 2+ years of relevant industry experience
  • Strong expertise in the design, execution, and validation of CRISPR/Cas9 gene editing experiments (knock-outs and knock-ins)
  • Expertise in molecular cloning techniques (PCR, Restriction digesting, Gibson/Infusion assembly, gel electrophoresis, plasmid prepping)
  • Skilled with primer design, Sanger sequencing, and molecular biology and sequence analysis software, such as SnapGene.
  • Experience with western blotting or similar protein expression assays
  • Expertise in multicolor flow cytometry in primary cells and analysis
  • Experience with GraphPad Prism and Microsoft Office Suite programs for data analysis, presentations and report and protocol writing.
  • High-level capability with mammalian tissue culture and primary T-cell culture
  • Ability to interpret results analytically in a timely manner and troubleshoot technical problems.
  • Great attention to detail. Agile and flexible mindset yet highly organized.
  • Ability to prioritize multiple tasks, work under various timeline pressures, drive tasks to completion, and anticipate and proactively develop mitigation strategies.
  • Previous experience with electronic lab notebooks (ELN).
  • The ability to perform in a start-up environment.
Responsibilities
  • Build – a robust cell engineering infrastructure to enable proof-of-concept experiments in primary immune cells
  • Perform over-expression, knock-out, and knock-in experiments in cell culture and primary cells
  • Design and produce expression and viral plasmids in support of program goals.
  • Maintain detailed and highly organized documentation of experimental procedures, SOPs, data, and generated products.
  • Analyze data in a timely manner and present findings at team/departmental meetings.
  • Demonstrate advanced knowledge of principles and techniques in molecular cloning, gene editing, and cell culture
  • Keep up to date - on industry knowledge and advancements; provide input on optimization of design, process, or capability.
  • Contribute – Be a subject matter expert and contribute to project direction, prioritization and mitigation strategies.
  • Mentor junior Research Associates to help them reach the next level
  • Collaborate - and work effectively with Discovery Biology, Translational Sciences and CMC teams.

Tr1X focuses on developing cellular immunotherapies aimed at treating autoimmune and inflammatory diseases. The company uses a unique platform to create cell therapy products that help to rebalance the immune system, promoting long-term tolerance in patients. Unlike many other companies in the biopharmaceutical sector, Tr1X specializes in first-in-class therapies that target the underlying immune dysfunctions associated with these diseases. The goal of Tr1X is to provide advanced therapeutic solutions that improve the quality of life for patients suffering from these conditions.

Company Stage

Series A

Total Funding

$73M

Headquarters

San Diego, California

Founded

2018

Growth & Insights
Headcount

6 month growth

20%

1 year growth

40%

2 year growth

40%
Simplify Jobs

Simplify's Take

What believers are saying

  • The $75M Series A financing led by prominent investors like The Column Group and NEVA SGR provides strong financial backing for rapid development and execution.
  • Initiating Phase 1 studies for GvHD and planning an IND for Crohn's disease in 2024 positions Tr1X for significant clinical milestones and potential market entry.
  • The off-the-shelf nature of TRX103 offers a cost-effective and scalable solution, potentially revolutionizing treatment paradigms for autoimmune and inflammatory diseases.

What critics are saying

  • The success of Tr1X heavily depends on the clinical outcomes of its Phase 1 studies, which are inherently uncertain.
  • The competitive landscape in cell therapy is intense, with numerous companies vying for FDA approvals and market share.

What makes Tr1X unique

  • Tr1X focuses on developing allogeneic regulatory T cell therapies (Allo-Tregs) and CAR-Treg cell therapies, setting it apart from competitors who may focus on autologous or other cell therapy approaches.
  • The company's highly scalable platform allows for efficient pipeline expansion, providing a competitive edge in rapidly addressing multiple autoimmune and inflammatory diseases.
  • FDA clearance for TRX103, the first ever allogeneic engineered Tr1 regulatory T cell product, underscores Tr1X's pioneering role in the cell therapy landscape.

Help us improve and share your feedback! Did you find this helpful?